---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270432"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:12:28.674976+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma receives two new US patent allowances for FIRDAPSE, extending IP protection to mid-2032

## Summary
- USPTO allowed two patents covering FIRDAPSE bioavailability under fasting/fed conditions; expected grant within two months.
- Patents expire mid-2032; will be listed in FDA Orange Book, raising total listed patents to eight.
- CEO states patent exclusivity in US until 2037; these new patents strengthen IP estate.
- FIRDAPSE is only approved US treatment for Lambert-Eaton myasthenic syndrome.

## SEC filing metadata
- accession: 0001193125-23-270432
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523270432/0001193125-23-270432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523270432/d583587d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270432
- JSON: https://secwatch.observer/filing/0001193125-23-270432.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.